You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

518 Results
Regimen
Cancer Type:
Skin, 
Basal Cell
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vismodegib - Treatment for metastatic basal cell carcinoma (BCC) or with locally advanced BCC (including patients with basal cell nevus syndrome, i.e. Gorlin syndrome), according to specific criteria
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
Sep 2022
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
Sep 2022
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Oct 2017
Regimen
Intent: Palliative
Nov 2024
Regimen
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
Oct 2020
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Ramucirumab - Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Oct 2017
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Intent: Palliative

Pages